Reactive astrocytes promote proteostasis in Huntington's disease through the JAK2-STAT3 pathway.
JAK2-STAT3 signalling
aggregated protein clearance
neurodegenerative diseases
neuron-astrocyte interactions
viral vectors
Journal
Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537
Informations de publication
Date de publication:
05 01 2023
05 01 2023
Historique:
received:
10
05
2021
revised:
13
01
2022
accepted:
24
01
2022
pubmed:
18
3
2022
medline:
11
1
2023
entrez:
17
3
2022
Statut:
ppublish
Résumé
Huntington's disease is a fatal neurodegenerative disease characterized by striatal neurodegeneration, aggregation of mutant Huntingtin and the presence of reactive astrocytes. Astrocytes are important partners for neurons and engage in a specific reactive response in Huntington's disease that involves morphological, molecular and functional changes. How reactive astrocytes contribute to Huntington's disease is still an open question, especially because their reactive state is poorly reproduced in experimental mouse models. Here, we show that the JAK2-STAT3 pathway, a central cascade controlling astrocyte reactive response, is activated in the putamen of Huntington's disease patients. Selective activation of this cascade in astrocytes through viral gene transfer reduces the number and size of mutant Huntingtin aggregates in neurons and improves neuronal defects in two complementary mouse models of Huntington's disease. It also reduces striatal atrophy and increases glutamate levels, two central clinical outcomes measured by non-invasive magnetic resonance imaging. Moreover, astrocyte-specific transcriptomic analysis shows that activation of the JAK2-STAT3 pathway in astrocytes coordinates a transcriptional program that increases their intrinsic proteolytic capacity, through the lysosomal and ubiquitin-proteasome degradation systems. This pathway also enhances their production and exosomal release of the co-chaperone DNAJB1, which contributes to mutant Huntingtin clearance in neurons. Together, our results show that the JAK2-STAT3 pathway controls a beneficial proteostasis response in reactive astrocytes in Huntington's disease, which involves bi-directional signalling with neurons to reduce mutant Huntingtin aggregation, eventually improving disease outcomes.
Identifiants
pubmed: 35298632
pii: 6550082
doi: 10.1093/brain/awac068
doi:
Substances chimiques
Huntingtin Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
149-166Subventions
Organisme : French National Research Agency
ID : ANR-11-EQPX-0029
Organisme : Fondation Maladies Rares
Organisme : Association Huntington France
Organisme : Region Ile-de-France
Organisme : Fondation pour la Recherche Medicale fellowship
ID : ARF201909009244
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.